Study of Medifast's effectiveness for weight control in patients with type
2 diabetes has been accepted for publication
OWINGS MILLS, Md., Oct. 15 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that a study conducted by researchers at the Johns Hopkins University Bloomberg School of Public Health has been accepted for publication in a peer-reviewed journal which is scheduled for release in an early 2008 issue. The study compared Medifast's effectiveness for weight control to the standard American Diabetes Association (ADA) recommended dietary guidelines.
"Weight loss is critical for controlling type 2 diabetes," said Michael S. McDevitt, Chief Executive Officer, Medifast, Inc. "Medifast is proud that our products are effective for people who suffer from this disease, and we will continue to work toward improving the health of people with type 2 diabetes."
For more than 25 years Medifast has been prescribed by practitioners as a safe and effective program that yields significant results either alone, or as a complementary low-calorie program with drug therapy. The Medifast brand will be further validated in the medical community, and by consumers, by a second new study recently submitted for publication. The second study which was conducted by researchers at a major university medical institution, shows favorable findings for the Medifast Program among individuals on appetite suppressant therapy.
The Medifast Program alone is proven to provide significant weight loss of 2-5 pounds per week. While the Company does not recommend the use of weight loss drugs, Medifast does recognize that diet pills are very much part of the landscape now and in the future. Medifast is a proven program that can ensure consumers are successful on drug therapy regimens that include a reduced calorie diet and lifestyle change in order to be effective. Medifast also works well with the current popular over-the-counter drug that recommends utilizing a low fat program.
The findings from studies at two university medical institutions only add to the medically approved history of the Medifast Program. Medifast has been recommended by over 15,000 physicians nationwide, and provides its customers with a network of health coaches and nutrition experts as well as a vast online support community.
More information regarding the inclusion of studies in peer-reviewed journals will become available at the time of publication.
Medifast (NYSE: MED) is the leading easy-to-use, clinically proven portion-controlled weight loss program. Medifast has been recommended by 15,000 physicians and used by over one million customers. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) national network of physicians, 3) medically supervised Medifast Weight Control Centers and 4) the Take Shape For Life direct-selling division, a network of health coaches. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information log onto http://www.ChooseMedifast.com.
|SOURCE Medifast, Inc.|
Copyright©2007 PR Newswire.
All rights reserved